46:I[185,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SendEmailButton"] 48:I[63625,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"AddToLibraryButton"] 49:I[29721,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ShareButton"] 4a:I[58016,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ProcessEpisodeButton"] 4b:I[45269,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SignupCTA"] 3f:["$","h1",null,{"className":"max-w-[22ch] font-display text-[clamp(32px,4.5vw,48px)] font-medium leading-[1.05] tracking-[-0.02em] text-[color:var(--fg-1)] text-balance","children":"Hoth Therapeutics, Inc. (NASDAQ: HOTH) Dermatological therapeutics pipeline targeting multi-billion dollar opportunities (+ near-term catalysts)"}] 40:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2019-09-04T22:10:40.000Z","children":"September 4, 2019"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:24:39"}],false]}] 47:T528,

Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be a featured presenter at Wall Street Reporter’s Next Super Stock Live! online investor conference on September 26, 2019.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Interview with CEO Robb Knie, discussing the company’s pipeline of unique targeted dermatological therapies, for indications including: eczema, psoriasis, chronic wound disorders, and acne which address multi-billion dollar market opportunities.

Robb provides an overview of the company’s BioLexa platform, and how it offers a shortened path towards regulatory approval, and the near-term catalysts for value creation.

Robb, also explains why Hoth is a compelling value proposition for investors based on recent M&A activity in the dermatological space, including the $4.9 billion paid by Pfizer (NYSE: PFE) for Anacor, whose lead product lead product, Eucrisa, is a topical treatment for mild to moderate eczema.

Hosted on Acast. See acast.com/privacy for more information.